Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

Table 1

Results of biochemical parameters in CKD patients and control group.

Biochemical parameters	CKD patients before treatment	CKD patients after treatment	Control group
	() (Me; 25–75%)	() (Me; 25–75%)	() (Me; 25–75%)
Hb (g/dL)	9.1 (8.7–10.0)	11.6 (11.1–12.1)	14.4 (13.3–14.9)
Creatinine (µmol/L)	269 (233–340)	271 (223–348)	90 (77–108)
eGFR (MDRD) (mL/min/1.73 m^2)	19.6 (15.5–22.8)	18 (15–24.2)	65 (63–74)
CRP (mg/L)	18 (14.1–22.8)	16 (12.2–20.4)	4.5 (3.7–6.9)
NT-proBNP (pg/mL)	355.6 (282.3–432.7)	302 (182.1–401.3)	75 (49–101)

⁢ versus control group; versus CKD patients before treatment.
CKD = chronic kidney disease, (Me; 25–75%) = median and interquartile range, Hb = hemoglobin, eGFR (MDRD) = estimated glomerular filtration rate (Modification of Diet in Renal Disease equation), CRP = C-reactive protein, and NT-proBNP = N-terminal pro-brain natriuretic peptide.